14th Annual Boston Atrial Fibrillation Symposium Proceedings – Technology Round Up
Corresponding Author:Dhanunjaya Lakkireddy MD, FACC,
Director – Center for Excellence in Atrial Fibrillation, Bloch Heart Rhythm Center,
University of Kansas Hospitals.
January 17th, 2009, Boston
What started off as a small, cozy meeting of electrophysiologists thinking about atrial
fibrillation (AF) evolved into a major annual program that draws more audience
every year. Thanks to the vision of Dr. Jeremy Ruskin (Massachussets General Hospital,
Boston) who started this program
and continues to direct it very effectively to this day. Over the last few
years, industry has used this as a good platform to showcase some of their
latest technology in AF therapy. Several products ranging from radiation
protection devices to most advanced mapping and ablation systems have been
displayed at the Seaport Hotel.
Sachin Vadodaria, Director , Marketing for St. Jude Medical was
very excited about their new AF technologies. Their latest additions included –
BRK-XS® Transseptal puncture needle
, that has a primary bevel at a more acute angle (30 degrees) and two back bevels that combine to form a
distinct point on the tip of the needle. This is an improvement from their
prior version and was found to have significant reduction in force needed to
cross the interatrial septum in in-vitro studies . This is currently
FDA approved and may be a good option for septa that are tough and scarred. Steerable transseptal
sheath called the Agilis NxT ® has
52 mm distal curve that could help the ablation or mapping catheters reach
difficult areas of the left atrium. Clinical studies using the prior version of
the Agilis sheath was found to be safe and
efficacious than the conventional fixed curve (Mullins) transseptal
sheaths . Effective
left atrial navigation especially for operators early
on their learning curve could be difficult and this sheath may facilitate that.
This sheath could definitely find some
use in severely enlarged and rotated hearts with difficult to reach pulmonary
veins to ensure better catheter stability. The additional operational benefit
compared to the additional costs over a fixed curve sheath for routine use is
yet to be tested. St. Jude also introduced a new high density multi ringed
spiral mapping catheter called Reflexion HD®.
This is a unique20 pole catheter on the same platform as their Reflexion spiral circular mapping catheter with
bidirectional curve but fixed diameter.
Clinical utility may come in for high density left atrial
mapping. This catheter could be used like a tradiational
circular mapping catheter to guide pulmonary vein isolation and specifically
for complex fractionated electrogram mapping. It may help
improve the speed and accuracy of left atrial maps
considerably. H Curve – TV is their new H-curve catheter with improved
flexibility and adjustable tricuspid valve diameter that works like a Halo
catheter for right atrial ablations (cavotricuspid isthmus).
There were a few other interesting technologies
related t o3D mapping that are pipeline pending FDA approval. Ensite Velocity® is one such system with
better processor speed and improved efficacy. This carries the version 9.0 of
the Ensite NavX software
with the attached bells and whistles.
||Agilis NxT ©
||Reflexion HD ©
||Reflexion Spiral ©
Bard Electrophysiology displayed the new 5 mm tip Scorpion 2 ® (4 pole2-5-2
mm separation) ablation
catheter. The unique feature of this
catheter is a bidirectional tip with proximal and distal curve control on a
single handle with a curve control lock. This feature of the catheter tip could
potentially help better tissue contact with parallel contact to tissue. In some
of the cavotricuspid isthmuses, adequate tissue
contact could be a challenge and this catheter could help stability. In the era
of open irrigated catheters, the role for this catheter is yet to be tested.
Efficacy data for this catheter system compared to the currently available 4mm,
8mm non irrigated and open irrigated catheters is not available.
Lechnologies Research Inc., showcased their new AfibAlert® external
heart rhythm monitor marketed to target AF patients. It seems to work on
similar platform like most of the existing external monitoring systems with two
wrist EKG patches and the finger insert for pulse check. It has six memory slots in its cascading
memory system that has the capability of storing one baseline EKG and five
recordings with new data replaces the old. Life Watch Inc,had recently released its ACT III monitor for AF
monitoring with extended memory, greater portability along with their online AF
monitoring program. Mednet,
Cardio Labs and Cardionet are some of the other
companies that have similar technologies.
To add to the existing list of monitoring related companies, Cardiostaff Corp from Austin,
TX brings in their mini digital recorder
and 30 day event recorder.
|Lifewatch ACT III monitorn ©
The much awaited magnetic irrigated catheter from Stereotaxis Inc may finally come to the United
States in a few months. Initial clinical
experience of this magnetic guided open irrigated catheter in complex left atrial ablations was found to have comparable short term
and long term success rates. The earlier attempts of release
in the United States was marred by technical problems and the concerns regarding
charr formation at the catheter tip. Currently Biosense Webster manufactures exclusively all the catheters
that are compatible with magnetic navigation system. There are other manufacturers who are
attempting to work on some of these navigation catheters. They also featured their Odyssey® compact
but comprehensive monitor that brings EP recording/monitor, 3D map, intracardiac echo and magnetic navigation to one large
screen. This is very user friendly and reduces the desk space in the control
Innovative is a France
based company that makes a radiation protection cabin called CATHPAX®. They
released their second iteration recently. This is the first alternative to the
traditional lead apron/skirt/vest that have been
around for several decades. This designed in the shape of a vertical cabin with
two holes for the operators hands at adjustable
height. The whole frame is mounted on wheels and can be moved around. A study from Hein Heidubuchel from Lueven, Belgium  clearly shows greater reductions in exposure to
head, legs and forearms that typically are not protected by the conventional
lead gear. There is no definite data on ergonomic aspects of operator
performance. This is definitely worth looking into for high volume operators of
prolonged procedures like AF ablation. Kinesiologic
impact on the operators is worth studying.
Phillips Medical has marketing rights to this system in the United
|CATHPAX II ©
Catheter technology seems to attract companies that have
traditionally been in device business. The latest additions are Biotronik and Medtronic. Biotronik has recently release their Alcath Flux Gold®, Trignum® and Lexx® catheters in Europe and are
working on feasibility and non-inferiority studies pending FDA approval in the United
States. Medtronic acquired Ablation Frontiers, a niche catheter company that makes multisite ablation catheters. Ablation Frontiers was Dr. Fred Morady’s (University
of Michigan, Ann
Arbor, MI) brain child that has
done well. Traditionally, RF could be delivered through a single tip limiting
the speed of applications in procedures that required extensive ablation. This
shortcoming of the traditional catheters was attempted to overcome by new
technologies that can burn simultaneously from multiple electrodes. Ablation
Frontiers pioneered that new technology releasing catheters of various shapes
with strategically located ablation electrodes. The most popular one was a
catheter on a circular platform with adjustable diameter for PV isolation. The
feasibility study results are encouraging.
Medtronic also acquired Cryo Cath Inc, a Canadian company that specializes in cryo ablation. Interestingly, Medtronic had stayed away
from catheter technologies for several years despite their early interest
(Mariner catheter & Localisa mapping system)
while its competitor St. Jude Medical Inc. continued its efforts to consolidate
its position in the catheter business.
Biosense Webster Inc, has been in catheter business for more than a decade.
They have tradiationally done well through their
CARTO 3D mapping system and non irrigated and open irrigated catheter. Their Thermocool® open irrigated catheter was a major
success and had recently
received an approval for use in AF ablations by FDA. CARTO Sound
integrates intracardiac echo with 3D mapping. CARTO-3
is their latest system with multi catheter visualization capability. Hansen Medical showed their new Sensei
robotic navigation system. They gained a significant market share in the united states
on therobotic front. Yet another robotic navigation
system, thatoperates on much smaller budgets has showcased their system.
No major detailsare available at this point in time.
Cardiofocus has brought out their
new laser balloon with changes made to the catheter platform and better
visibility. To remind the readers, Cardiofocus had
prematurely terminated their initial study using the earlier version of their
balloon catheter due to complications from cardiac perforation. Steve Sagon, the CEO of Cardiofocus
discussed with JAFIB about starting a new feasibility trial in the United
States very soon and is trying to recruit
some prestigious institutions to do the trial.
|Cardiofocus Laser Balloon Ablation Catheter ©
Catheter Robotics Inc., has
developed a new robotic catheter system with remote navigation capabilities.
This is in its very early stages of development and no major clinical data is
|Catheter Robotics Navigation System ©
Disclaimer : This is a pure technical review of the products and JAFIB does not endorse any of these products.
Piorkowski C, Kottkamp H, Gerds-Li JH et al. Steerable sheath catheter navigation for ablation of atrial fibrillation: A case control study. PACE 2008;31:863-873
Dragusin O, Weerasooriya R, Jaïs P, Hocini M, Ector J, Takahashi Y, Haïssaguerre M, Bosmans H, Heidbüchel H.Eur Heart J. 2007 Jan;28(2):183-9.